Search Close



Dr Cliff Holloway (CEO)

Cliff brings over 25 years of life science industry experience to Scancell in the development and commercialisation of emerging technologies and therapeutic products including licensing, M&A, corporate financing and operations management. Most recently he was Chief Business and Operating Officer of Benitec Biopharma Ltd (ASX:BLT, NASDAQ:BNTC). Prior to his role at  Benitec he held the position of Managing Director at Sienna Cancer Diagnostics Ltd (ASX:SDX), and also for therapeutic antibody development companies Immune System Therapeutics Ltd and Biosceptre International Ltd. He was formerly VP of Business Development at Arana Therapeutics Ltd, which was acquired by US-based Cephalon Inc (now Teva) in 2009, and he is currently a director of investment fund Newstar Ventures Pty Ltd. Cliff holds a Bachelor of Pharmacy and a PhD in Medicinal Chemistry from the University of Nottingham.

Professor Lindy Durrant (CSO)

Lindy is an internationally recognised immunologist in the field of tumour therapy, She has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies for diagnostic imaging and therapy and cancer vaccines. She has a personal Chair in Cancer Immunotherapy at the Department of Clinical Oncology at the University of Nottingham.

Dr Sally Adams (Development Director)

Dr Sally Adams was Head of Neurology & Virology at British Biotech and Development Director at Neures Limited before becoming an independent consultant providing drug development and management services within the biotechnology and pharmaceutical sectors, specialising in biological entities.  She has worked on many complex projects over the past 25 years including anti-infective vaccines, cancer immunotherapies and an innovative stem cell treatment for visual dysfunction.  Sally previously  worked as a development consultant to  Scancell, providing guidance on the development  of SCIB1, before her appointment as Development Director in May 2014.

Keith Green (Director of Finance & Administration )

Keith trained and qualified as a chartered accountant with Peat Marwick (now KPMG). He spent twenty years in the accounting profession before joining a private medical diagnostic company as Financial Director. Since 2003 he has taken on many consultancy and interim finance roles for private and AIM listed companies in the life sciences sector. Keith started working for Scancell on a part-time basis in January 2010 and took up this full-time role in September 2016.

Webcasts, Interviews and Media Coverage

Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

Tue, 12 Feb 2019 15:07:00

Scancell lauds another six months of progress

The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".

Thu, 31 Jan 2019 08:41:00

Award shortlist 'a significant scientific endorsement' of Scancell's technology

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive London's Andrew Scott the company's received “significant scientific endorsement” of its technology after it and a group of collaborators were shortlisted for a major award.

It teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

Wed, 23 Jan 2019 12:25:00